{"id":49884,"date":"2022-10-20T20:01:55","date_gmt":"2022-10-20T18:01:55","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\/"},"modified":"2022-10-20T20:01:55","modified_gmt":"2022-10-20T18:01:55","slug":"veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\/","title":{"rendered":"Veranex Announces Tom Daulton as CEO and Appointment of David Dockhorn to New COO Role"},"content":{"rendered":"
\n

RALEIGH, N.C.–(BUSINESS WIRE)–Veranex<\/a>, the only truly comprehensive, global, tech-enabled service provider dedicated to the MedTech industry, announced today the appointment of industry veteran Tom Daulton as chief executive officer (CEO). David Dockhorn, who previously served in this role, is assuming the newly created role of chief operating officer (COO).\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nTom Daulton<\/a> brings over 30 years of healthcare leadership experience to Veranex, joining from National Dentex Labs (NDX), where he served as chairman and CEO for the past seven years and built one of the largest dental lab networks in North America. His additional experience includes key roles at medical device and healthcare services organizations with global scale, including 20 years at Baxter, Allegiance Healthcare, and Cardinal Health. Daulton was also founder and CEO of Devicor Medical Products, which acquired Mammotome\u2019s breast care business from Johnson & Johnson\u2019s Ethicon Endo-Surgery. The addition of Daulton will further expand extensive device experience across the Veranex executive suite.\n<\/p>\n

\n\u201cI am thrilled to join this exceptional team and continue the progress David has already championed,\u201d Daulton said. \u201cAs an end-to-end MedTech service provider, Veranex is clearly poised for an exciting future. My background \u2014 including experience building two large global healthcare businesses \u2014 has afforded me a solid understanding of how to knit a variety of cultures together into a powerful, unified business. I look forward to working closely with the team to build on Veranex\u2019s role as a leader in MedTech innovation, providing comprehensive solutions to our customers and continuing to raise the industry standard for both quality and speed to market.\u201d\n<\/p>\n

\nIn his new role as COO, David Dockhorn<\/a> will focus on operational excellence as Veranex continues its global expansion through both acquisition-driven and organic growth. He will support Daulton in business integration and in building the organizational structure necessary to support Veranex\u2019s growing global footprint.\n<\/p>\n

\n\u201cI am proud of the company we are building and the impact we are making every day with our customers,\u201d Dockhorn said. \u201cOur global team has worked to build a company that uniquely addresses the whole suite of MedTech customer needs \u2014 from medical device discovery to invention, manufacturing, preclinical, clinical\/regulatory, market launch, and commercial \u2014 allowing our clients to work on a global scale. I am excited to strengthen our impact by focusing on building the operational teams that support organic growth as we continue to build out our capabilities and enhance our operations, while Tom focuses on leading the organization and helping it expand.\u201d\n<\/p>\n

\n\u201cThe Veranex board is thrilled to welcome Tom to lead the company through this next stage of growth,\u201d said Veranex Board of Directors Chairman Patrick Donnelly<\/a>. \u201cTom is a proven leader with deep experience in MedTech and in leading global companies. His experience, combined with David\u2019s operational leadership expertise, enables Veranex to deepen our capability to help our clients deliver innovation that has a true impact on the lives of patients everywhere.\u201d\n<\/p>\n

\nAbout Veranex<\/b>\n<\/p>\n

\nVeranex is the only truly comprehensive, global, tech-enabled service provider dedicated to the MedTech industry. Offering expert guidance from concept to commercialization and across the development continuum, Veranex enables accelerated speed to market, controlled development costs, development risk mitigation, and accelerated market viability assessment. At every stage, Veranex customers realize efficiencies in cost and time, while its comprehensive solutions unify and streamline the entire development process. Veranex is backed by Summit Partners<\/a>, Accelmed<\/a>, and Lauxera Capital Partners<\/a>. For more information, visit VeranexSolutions.com<\/a> and follow Veranex on LinkedIn<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nLindsey Langemeier
\n
SCORR Marketing
\n
+1 402-405-4269
\n
lindsey@scorrmarketing.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

RALEIGH, N.C.–(BUSINESS WIRE)–Veranex, the only truly comprehensive, global, tech-enabled service provider dedicated to the MedTech industry, announced today the appointment of industry veteran Tom Daulton as chief executive officer (CEO). David Dockhorn, who previously served in this role, is assuming the newly created role of chief operating officer (COO). Tom Daulton brings over 30 years … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49884","6":"format-standard","7":"category-industry"},"yoast_head":"\nVeranex Announces Tom Daulton as CEO and Appointment of David Dockhorn to New COO Role - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Veranex Announces Tom Daulton as CEO and Appointment of David Dockhorn to New COO Role - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"RALEIGH, N.C.–(BUSINESS WIRE)–Veranex, the only truly comprehensive, global, tech-enabled service provider dedicated to the MedTech industry, announced today the appointment of industry veteran Tom Daulton as chief executive officer (CEO). David Dockhorn, who previously served in this role, is assuming the newly created role of chief operating officer (COO). Tom Daulton brings over 30 years ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-20T18:01:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221020005940\/en\/1609263\/21\/Veranex_Daulton_Dockhorn.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Veranex Announces Tom Daulton as CEO and Appointment of David Dockhorn to New COO Role\",\"datePublished\":\"2022-10-20T18:01:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\\\/\"},\"wordCount\":600,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221020005940\\\/en\\\/1609263\\\/21\\\/Veranex_Daulton_Dockhorn.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\\\/\",\"name\":\"Veranex Announces Tom Daulton as CEO and Appointment of David Dockhorn to New COO Role - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221020005940\\\/en\\\/1609263\\\/21\\\/Veranex_Daulton_Dockhorn.jpg\",\"datePublished\":\"2022-10-20T18:01:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221020005940\\\/en\\\/1609263\\\/21\\\/Veranex_Daulton_Dockhorn.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221020005940\\\/en\\\/1609263\\\/21\\\/Veranex_Daulton_Dockhorn.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Veranex Announces Tom Daulton as CEO and Appointment of David Dockhorn to New COO Role\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Veranex Announces Tom Daulton as CEO and Appointment of David Dockhorn to New COO Role - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\/","og_locale":"en_US","og_type":"article","og_title":"Veranex Announces Tom Daulton as CEO and Appointment of David Dockhorn to New COO Role - Pharma Trend","og_description":"RALEIGH, N.C.–(BUSINESS WIRE)–Veranex, the only truly comprehensive, global, tech-enabled service provider dedicated to the MedTech industry, announced today the appointment of industry veteran Tom Daulton as chief executive officer (CEO). David Dockhorn, who previously served in this role, is assuming the newly created role of chief operating officer (COO). Tom Daulton brings over 30 years ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-20T18:01:55+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221020005940\/en\/1609263\/21\/Veranex_Daulton_Dockhorn.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Veranex Announces Tom Daulton as CEO and Appointment of David Dockhorn to New COO Role","datePublished":"2022-10-20T18:01:55+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\/"},"wordCount":600,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221020005940\/en\/1609263\/21\/Veranex_Daulton_Dockhorn.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\/","url":"https:\/\/pharma-trend.com\/en\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\/","name":"Veranex Announces Tom Daulton as CEO and Appointment of David Dockhorn to New COO Role - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221020005940\/en\/1609263\/21\/Veranex_Daulton_Dockhorn.jpg","datePublished":"2022-10-20T18:01:55+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221020005940\/en\/1609263\/21\/Veranex_Daulton_Dockhorn.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221020005940\/en\/1609263\/21\/Veranex_Daulton_Dockhorn.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/veranex-announces-tom-daulton-as-ceo-and-appointment-of-david-dockhorn-to-new-coo-role\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Veranex Announces Tom Daulton as CEO and Appointment of David Dockhorn to New COO Role"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49884"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49884\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}